Brief: Spectral Medical Enrolls Patient 82 In Its Phase 3 FDA Tigris Septic Shock Trial
10/01/2024 12:21
Jan 10 (Reuters) - Spectral Medical Inc EDT.TO :
* SPECTRAL MEDICAL ENROLLS PATIENT 82 IN ITS PHASE 3 FDA
TIGRIS
SEPTIC SHOCK TRIAL
* SPECTRAL MEDICAL INC- APPROACHING INTERIM ENROLLMENT
TARGET OF
90 PATIENTS
Source text for Eikon: ID:nGNX4zpMXK
Further company coverage: EDT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%